Blood Parameter Analysis Establish Prognosis for Brain Metastases Patients
By LabMedica International staff writers Posted on 07 Oct 2015 |
Image: Gross pathology of brain metastasis from a thyroid papillary carcinoma (Photo courtesy of Dr. Nikola Kostich).
Certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.
Brain metastases are secondary tumors that have spread from primary tumors at other sites in the body such as lungs, breast or skin, for example. Approximately 40% of all patients with metastasized cancer develop metastases in their brain.
Scientists at the Medical University of Vienna (Austria ) conducted a study which included 1,201 patients with different primary cancers. They analyzed blood parameters that had not so far been included in oncological prognosis scores. The results show that subnormal levels of red blood pigment (hemoglobin), blood platelets (thrombocytes), white blood cells (leucocytes) and albumin (the main plasma protein) and elevated levels of serum creatinine, lactate dehydrogenase and the inflammatory markers C-reactive protein (CRP) were associated with poorer survival from brain metastases.
The commonest type of malignant brain tumors, are difficult to treat, often cause severe symptoms, such as intense headaches, neurological problems or epilepsy and are often associated with a limited life expectancy. Nevertheless, there are some patients who survive for a long time, despite their brain metastases. Anna Sophie Berghoff, PhD, the lead author of the study, said, “We asked ourselves whether there are any objective parameters that can provide us with a more stable basis for establishing an accurate prognosis for patients. This is not only important for estimating their life expectancy or for their inclusion in clinical studies but also for deciding on the most appropriate treatment for them.”
Dr. Berghoff, added, “This study has enabled us to show that the investigated parameters have a strong, independent prognostic impact and are therefore to be regarded as objective parameters. This is particularly true of hemoglobin levels and the concentration of CRP and lactate dehydrogenase." The team is now recommending that the last three parameters, in particular, be tested in follow-up studies for inclusion in prognosis scores. The study was presented at the European Cancer Congress ECC2015, held September 25–29, 2015, in Vienna (Austria).
Related Links:
Medical University of Vienna
Brain metastases are secondary tumors that have spread from primary tumors at other sites in the body such as lungs, breast or skin, for example. Approximately 40% of all patients with metastasized cancer develop metastases in their brain.
Scientists at the Medical University of Vienna (Austria ) conducted a study which included 1,201 patients with different primary cancers. They analyzed blood parameters that had not so far been included in oncological prognosis scores. The results show that subnormal levels of red blood pigment (hemoglobin), blood platelets (thrombocytes), white blood cells (leucocytes) and albumin (the main plasma protein) and elevated levels of serum creatinine, lactate dehydrogenase and the inflammatory markers C-reactive protein (CRP) were associated with poorer survival from brain metastases.
The commonest type of malignant brain tumors, are difficult to treat, often cause severe symptoms, such as intense headaches, neurological problems or epilepsy and are often associated with a limited life expectancy. Nevertheless, there are some patients who survive for a long time, despite their brain metastases. Anna Sophie Berghoff, PhD, the lead author of the study, said, “We asked ourselves whether there are any objective parameters that can provide us with a more stable basis for establishing an accurate prognosis for patients. This is not only important for estimating their life expectancy or for their inclusion in clinical studies but also for deciding on the most appropriate treatment for them.”
Dr. Berghoff, added, “This study has enabled us to show that the investigated parameters have a strong, independent prognostic impact and are therefore to be regarded as objective parameters. This is particularly true of hemoglobin levels and the concentration of CRP and lactate dehydrogenase." The team is now recommending that the last three parameters, in particular, be tested in follow-up studies for inclusion in prognosis scores. The study was presented at the European Cancer Congress ECC2015, held September 25–29, 2015, in Vienna (Austria).
Related Links:
Medical University of Vienna
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines